

K971516

000043

SUMMARY OF SAFETY EFFECTIVENESS

I. General Provisions

Common or Usual Name: PTA Balloon Catheter

Proprietary Name: PowerFlex™ Plus PTA Balloon Catheter

JUL 23 1997

II. Name of Predicate Devices

- Cordis PowerFlex PTA Balloon Catheter
- Cordis Opta5 PTA Balloon Catheter
- Cordis Small Vessel PTA Balloon Catheter
- Cordis Savvy PTA Balloon Catheter
- Cordis Mega PTA Balloon Catheter
- Meditech UltraThin Balloon Catheter

III. Classification

Class II

IV. Performance Standards

Performance standards have not been established by the FDA under section 514 of the Food, Drug and Cosmetic Act.

V. Intended Use and Device Description

The PowerFlex Plus PTA balloon catheter is intended to dilate stenoses in iliac, femoral, ilio-femoral, popliteal, infra popliteal and renal arteries, and for treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae.

The Cordis PowerFlex Plus PTA balloon catheter is a dual lumen design with a distal inflatable balloon. Two radiopaque marker bands indicate the dilating section of the balloon and aid in balloon placement.

All balloons distend to sizes above the nominal size at pressures greater than the nominal pressure.

The balloon inflation lumen is used to inflate and deflate the balloon. The nominal balloon size is printed on the hub.

The guidewire lumen is used to track the catheter over a prepositioned guidewire or to inject contrast medium and/or saline. The maximum injection pressure is 450 psi. The compatible guidewire size, catheter shaft French size and catheter length are printed on the hub. The radiopaque marker bands indicate the stated nominal length of the balloon.

VI. Biocompatibility

All materials used in the PowerFlex Plus PTA balloon catheter are biocompatible.

VII. Summary of Substantial Equivalence

The Cordis PowerFlex Plus PTA balloon catheter and the referenced Cordis PowerFlex PTA balloon catheter, Cordis Opta5 PTA balloon catheter, Cordis Small Vessel PTA balloon catheter, Cordis Savvy PTA balloon catheter, Cordis Mega PTA balloon catheter and Meditech UltraThin balloon catheter are similar in their basic design, construction, indication for use and performance characteristics.



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

JUL 23 1997

Ms. Jan Pieter Kappelle
Cordis Corporation
14201 N.W. 60th Avenue
Miami Lakes, Florida 33014

Re: K971516
PowerFlex™ PTA Balloon Catheter
Regulatory Class: II (two)
Product Code: 74 LIT
Dated: April 25, 1997
Received: April 28, 1997

Dear Ms. Kappelle:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Pre-market Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your pre-market notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2 - Ms. Jan Pieter Kappelle

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4639. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,



Thomas J. Callahan, Ph.D.
Director
Division of Cardiovascular,
Respiratory, and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

510(k) Number (if known):

Device Name: Cordis PowerFlex™ Plus PTA Balloon Catheter

Indications for Use:

The PowerFlex Plus PTA Balloon Catheter is intended to dilate stenoses in iliac, femoral, ilio-femoral, popliteal, infra popliteal and renal arteries, and for treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae.

Tant R
 (Division Sign-
 Division of C
 and Neurolog
 510(k) Number: K971516

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IS NEEDED

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use
(Per 21 CFR 801.109)

OR

Over-The-Counter Use